Boomfish Wealth Group LLC Buys 2,900 Shares of Intuitive Surgical, Inc. $ISRG

Key Points

• Boomfish Wealth Group more than doubled its Intuitive Surgical position in the third quarter, adding 2,900 shares to hold 5,469 shares valued at approximately $2.224 million.
• Intuitive Surgical reported strong third-quarter results, with revenue rising 21.7% year over year to $3.05 billion and EPS of $3.00, beating analysts’ $2.65 estimate.
• Despite robust results and mostly bullish analyst ratings, investors remain concerned about slowing U.S. da Vinci procedure growth, margin pressure from a roughly $450 million antitrust settlement, and the stock’s elevated valuation.

Boomfish Wealth Group LLC raised its position in shares of Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report) by 112.9% during the third quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 5,469 shares of the medical equipment provider's stock after acquiring an additional 2,900 shares during the period. Boomfish Wealth Group LLC's holdings in Intuitive Surgical were worth $2,224,000 as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also made changes to their positions in ISRG. Bank of America Corp DE raised its position in Intuitive Surgical by 3.3% in the 1st quarter. Bank of America Corp DE now owns 3,616,973 shares of the medical equipment provider's stock worth $1,667,388,000 after purchasing an additional 116,292 shares during the period. Bank of New York Mellon Corp bought a new stake in Intuitive Surgical in the second quarter worth about $1,335,753,000. Amundi boosted its position in shares of Intuitive Surgical by 8.6% during the first quarter. Amundi now owns 2,428,356 shares of the medical equipment provider's stock valued at $1,119,448,000 after buying an additional 193,096 shares during the period. Arrowstreet Capital Limited Partnership grew its stake in shares of Intuitive Surgical by 95.3% during the first quarter. Arrowstreet Capital Limited Partnership now owns 2,105,544 shares of the medical equipment provider's stock valued at $970,635,000 after buying an additional 1,027,475 shares during the last quarter. Finally, Janus Henderson Group PLC grew its stake in shares of Intuitive Surgical by 3.7% during the first quarter. Janus Henderson Group PLC now owns 1,643,060 shares of the medical equipment provider's stock valued at $757,489,000 after buying an additional 58,587 shares during the last quarter. Hedge funds and other institutional investors own 83.64% of the company's stock.

Insider Buying and Selling at Intuitive Surgical

In related news, EVP Gary Loeb sold 400 shares of the stock in a transaction that occurred on Monday, August 10th. The shares were sold at an average price of $379.00, for a total transaction of $151,600.00. Following the completion of the sale, the executive vice president owned 5,320 shares of the company's stock, valued at $2,016,280. This represents a 6.99% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, Director Gary S. Guthart sold 10,000 shares of the stock in a transaction that occurred on Tuesday, August 11th. The shares were sold at an average price of $400.00, for a total transaction of $4,000,000.00. Following the sale, the director directly owned 1,245,679 shares of the company's stock, valued at $498,271,600. The trade was a 0.80% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last quarter, insiders sold 12,370 shares of company stock valued at $4,891,989. 0.60% of the stock is currently owned by corporate insiders.

Key Intuitive Surgical News

Here are the key news stories impacting Intuitive Surgical this week:

• Positive Sentiment: Intuitive Surgical reported third-quarter revenue of approximately $3.05 billion, up more than 20% year over year, while earnings exceeded consensus expectations. The company also highlighted continued international expansion and adoption of its robotic-surgery systems. Intuitive Surgical Stock: Margin Hit Masks Strong Q3 Growth Story
• Positive Sentiment: Several firms remain constructive: BTIG, Stifel Nicolaus, Piper Sandler, and Oppenheimer reaffirmed or maintained Buy ratings. Baird also raised its price target, while Erste Group upgraded the stock to Buy. ISRG was added to the Zacks Rank #1 Strong Buy list. New Strong Buy Stocks for October 23rd
• Neutral Sentiment: The quarter included roughly $450 million of costs tied to an antitrust settlement, along with pricing-related pressure, which reduced margins. These items appear largely nonrecurring, but investors are assessing their effect on near-term profitability. Intuitive Surgical Reports Q3 2026 Earnings Impacted by $450M Antitrust Settlement
• Negative Sentiment: The key concern is that U.S. da Vinci procedure growth slowed to its lowest level since the COVID period. Investors worry that decelerating domestic demand could make it harder for Intuitive Surgical to sustain its premium valuation, which remains above 50 times earnings. Intuitive Surgical Sinks as U.S. da Vinci Growth Slows
• Negative Sentiment: RBC lowered its expectations for ISRG, and an analyst downgrade contributed to a gap lower in the shares. The market is emphasizing forward growth and valuation rather than the headline earnings beat. Intuitive Surgical Shares Gap Down Following Analyst Downgrade

Intuitive Surgical Stock Performance

NASDAQ ISRG opened at $452.29 on Friday. The company has a market cap of $156.78 billion, a PE ratio of 54.69, a P/E/G ratio of 3.31 and a beta of 1.46. The firm's 50 day moving average price is $395.50 and its 200-day moving average price is $409.13. Intuitive Surgical, Inc. has a 52-week low of $328.57 and a 52-week high of $603.88.

Intuitive Surgical (NASDAQ:ISRG - Get Free Report) last posted its earnings results on Tuesday, October 20th. The medical equipment provider reported $3.00 earnings per share for the quarter, topping analysts' consensus estimates of $2.65 by $0.35. Intuitive Surgical had a return on equity of 18.17% and a net margin of 25.54%. The company had revenue of $3.05 billion during the quarter, compared to analyst estimates of $2.91 billion. During the same quarter in the prior year, the business earned $2.40 earnings per share. Intuitive Surgical's revenue was up 21.7% on a year-over-year basis. On average, analysts forecast that Intuitive Surgical, Inc. will post 8.87 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities research analysts have recently weighed in on ISRG shares. Citigroup reduced their price target on Intuitive Surgical from $590.00 to $500.00 and set a "buy" rating on the stock in a report on Friday, July 17th. Evercore set a $430.00 price objective on Intuitive Surgical in a report on Monday, July 6th. Wells Fargo & Company reaffirmed an "overweight" rating and issued a $486.00 price objective (down from $487.00) on shares of Intuitive Surgical in a research report on Wednesday. TD Cowen reiterated a "buy" rating and issued a $485.00 target price on shares of Intuitive Surgical in a research note on Monday. Finally, Leerink Partners set a $503.00 target price on Intuitive Surgical and gave the stock an "outperform" rating in a research report on Wednesday. Twenty-three research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company's stock. Based on data from MarketBeat.com, the stock has an average rating of "Moderate Buy" and a consensus price target of $493.54.

About Intuitive Surgical

Intuitive Surgical, Inc develops and manufactures robotic-assisted systems and related technologies for minimally invasive surgery. Its products are designed to help surgeons perform procedures through small incisions while providing enhanced visualization, precision and control. The company's primary platform is the da Vinci Surgical System, which is used across a range of specialties, including urology, gynecology, general surgery, cardiothoracic surgery and other procedures.

The company also offers the Ion endoluminal system, which is designed to support minimally invasive lung biopsy procedures.

Want to see what other hedge funds are holding ISRG? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Intuitive Surgical, Inc. (NASDAQ:ISRG - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.